List view / Grid view
20 December 2022 | By Eurofins DiscoverX Corp.
In this webinar, we present an approach for building MOA-based, simple, ready-to-use GLP-1 and GLP-2 bioassays and discuss assay validation results from Eurofins BPT.
US researchers find that a modified immune protein harming brain connections is much more common in the brains of women with Alzheimer’s, compared to men.
Dr Douglas Ross-Thriepland and Dr David Walter, from the Functional Genomics Centre (FGC) – a joint venture between Cancer Research UK’s (CRUK) drug discovery engine, Cancer Research Horizons, and AstraZeneca – speak to Drug Target Review about their work. The centre’s focus is on genetic screening; cancer models; CRISPR reagent…
Scottish researchers uncovered that drugs used to treat angina and high blood pressure, could be used to treat AKI.
Today’s drug screening methods use one or two types of data. However, disease biology is not replicable by simple screening models because diseases are complex and heterogenous. However, advanced screening methods that process dozens of data sources at one time have uncovered novel hits that have been overlooked across the…
Japanese researchers proposed using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama Muscular Dystrophy (FCMD).
US researchers have discovered a link between protein misfolding and liver cancer, that could help improve gene therapy for haemophilia.
US researchers, using new machine learning techniques have developed a virtual molecular library of “words” that encode commands to kill cancer cells.
This application note discusses why CAR T-cell therapy is so exciting, notes some common hurdles in development and manufacturing and proposes ddPCR technology as a solution for some of these issues.
This article outlines three innovative studies that use nanotechnology to deliver a new immunotherapy approach towards cancers.
Elevated lipoprotein(a), or Lp(a), is a major risk factor for cardiovascular disease that affects one in five people worldwide, but currently lacks approved therapies. Here, Dr Giles Campion, EVP, Head of R&D and Chief Medical Officer of Silence Therapeutics, describes the company’s approach to developing an investigational siRNA therapy designed…
Blocking a process called trogocytosis could enhance the ability of CAR T-cell therapies to treat cancer, according to research led by University of Pennsylvania scientists. In this Q&A, Dr Serge Fuchs, Elizabeth and William Whitney Clark Professor of Oncology at the University of Pennsylvania School of Veterinary Medicine, US, discusses…
US researchers have shown that CAR-T therapy can be used to eliminate unwanted cells that cause autoimmunity.
In this ebook are articles on immune checkpoint inhibitors and enhancing CAR T-cell therapies.
CIRM grant will fund novel gene therapy that aims for single lifelong treatment of Friedreich’s ataxia, a progressive neuromuscular disorder; a second CIRM grant will advance efforts to leverage UC San Diego research on another rare disease
